Our results also indicate that the erbB-2-overexpressing subtype of breast cancer may be more susceptible to the anti-cancer effects of buformin, due to the inhibition of numerous signaling molecules associated with RTK, especially erbB-2, signaling pathways. Here, ERBB2 is linked to cancer.